The recent outbreak of severe acute respiratory syndrome (SARS), which is an acute respiratory illness, is caused by newly discovered SARS coronavirus (SARS-CoV). Herein we describe the antiviral activity of several classes of nucleoside analogues evaluated against SARS-CoV in Vero 76 cells, some of which exhibited moderate activity.
PaiBalakrishna SLiuS-HZhuY-LChuCK & ChengY-C (1996) Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5- methyl-β-L-arabinofuranosyl uracil. Antimicrobial Agents & Chemotherapy40: 380–386.
2.
BarnardDLDayCWBaileyKHeinerMMontgomeryRLauridsenLWinslowSHoopesJLiJKLeeJCarsonDACottamHB & SidwellRW (2006) Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Research71: 53–63.
3.
ChenLRWangYCLinYWChouSYChenSFLiuLTWuYTKuoCJChenTSS, & JuangSH (2005) Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorganic Medicinal Chemistry Letters15: 3058–3062.
4.
ChenXZhouWSchinaziRF & ChuCK (2004) Synthesis of 3′-fluoro-2′,3′-dideoxy-2′,3′-didehydro-4′-ethynyl-D- and -L-furanosyl nucleosides. Journal of Organic Chemistry69: 6034–6041.
5.
ChooHChenXYadavVWangJSchinaziRF & ChuCK (2006) Synthesis and anti-HIV activity of D- and L-thietanose nucleosides. Journal of Medicinal Chemistry49: 1635–1647.
6.
ChunBKSchinaziRFChengYC & ChuCK (2000) Synthesis of 2′,3′-dideoxy-3′-fluoro-L-ribonucleosides as potential antiviral agents from D—sorbitolCarbohydrate Research328: 49–59.
7.
DrostenCGuntherSPreiserWVan der WerfSBrodtHRBeckerSRabenauHPanningMKolesnikovaLFouchierRABergerABurguiereAMCinatlJEickmannMEscriouNGrywnaKKrammeSManuguerraJCMullerSRickertsVSturmerMViethSKlenkHDOsterhausADSchmitzH & DoerrHW (2003) Identification of a novel coronavirus in patients with Severe Acute Respiratory Syndrome. The New England Journal of Medicine348: 1967–1976.
8.
GadthulaSSchinaziRF & ChuCK (2005) Synthesis and anti-HIV activity of β-D-3′-azido-2′,3′-unsaturated nucleosides and β–D-3′-azido-3′-deoxyribofuranosyl nucleosides. Nucleosides Nucleotides & Nucleic Acids24: 1707–1727.
9.
HoeverGBaltinaLMichaelisMBaltinaKondratenko LTolstikovGADoerrHW & CinatlJJr. (2005) Antiviral activity of glycyrrhizic acid derivatives against SARS-Coronavirus. Journal of Medicinal Chemistry48: 1256–1259.
10.
KorenGKingSKnowlesS & PhillipsE (2003) Ribavirin in the treatment of SARS: A new trick for an old drug?Canadian Medical Association Journal168: 1289–1292.
11.
KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySTongSUrbaniCComerJALimWRollinPEDowellSFLingAEHumphreyCDShiehWJGuarnerJPaddockCDRotaPFieldsBDeRisiJYangJYCoxNHughesJMLeDucJWBelliniWJ & AndersonLJ (2003) A novel coronavirus associated with Severe Acute Respiratory Syndrome. The New England Journal of Medicine. 348: 1953–1966.
12.
LeeNHuiDWuAChanPCameronPJoyntGMAhujaAYungMYLeungCBToKFLuiSFSzetoCCChungS & SungJJ (2003) A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. The New England Journal of Medicine. 348: 1986–1994.
13.
LiangCMaTCooperwoodJSDuJ & ChuCK (1997) Synthesis of L-ribofuranosyl C-nucleosidesCarbohydrate Research303: 33–38.
14.
MorgensternBMichaelisMBaerPCDoerrHW & CinatlJr. (2005) Ribavirin and interferon-(synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochemical & Biophysical Research Communications326: 905–908.
15.
PeirisJSLaiSTPoonLLGuanYYamLYLimWNichollsJYeeWKYanWWCheungMTChengVCChanKHTsangDNYungRWNgTK & YuenKY (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. The Lancet361: 1319–1325.
16.
PeirisJSChuCMChengVCChanKSHungIFPoonLLLawKITangBSHonTYChanCSChanKHNgJSZhengBJNgWLLaiRWGuanY & YuenKY (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. The Lancet361: 1767–1772.
17.
PoutanenSMLowDEHenryBFinkelsteinSRoseDGreenKTellierRDrakerRAdachiDAyersMChanAKSkowronskiDMSalitISimorAESlutskyASDoylePWKrajdenMPetricMBrunhamRC & McGeerAJ (2003) Identification of Severe Acute Respiratory Syndrome in Canada. The New England Journal of Medicine. 348: 1995–2005.
18.
SongGYPaulVChooHMorreyJSidwellRWSchinaziRF & ChuCK (2001) Enantiomeric synthesis of D- and L-cyclopentenyl nucleosides and their antiviral activity against HIV and West Nile Virus. Journal of Medicinal Chemistry44: 3985–3993.
19.
SureyyaO & ChuCKZ (2001) Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-L-arabinofuranosyl 1,2,3-triazole derivatives. Naturforsch. B56: 804–811.
20.
WenzelRP & EdmondMB (2003) Managing SARS amidst uncertainty. The New England Journal of Medicine. 348: 1947–1948.
21.
WuC-JHuangH-WLiuC-YHongC-F & ChanY-L (2005) Inhibition of SARS-CoV replication by siRNA. Antiviral Research65: 45–48.
22.
XiaoZLiYChenRLiSZhongS & ZhongN (2003) A retrospective study of 78 patients with severe acute respiratory syndrome. Chinese Medical Journal116: 805–810
23.
ZhangH-ZZhangHKemnitzerWTsengBCinatlJJrMichaelisMDoerrHW & CaiSX (2006) Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent Severe Acute Respiratory Syndrome Coronovirus (SARS-CoV) Inhibitors. Journal of Medicinal Chemistry49: 1198–1201.
24.
ZhongNS & ZengGQ (2003) Our strategies for fighting Severe Acute Respiratory Syndrome (SARS)American Journal of Respiratory & Critical Care Medicine168: 7–9.
